# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Multiple Technology Appraisal (MTA)

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

## Provisional matrix of consultees and commentators

<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Manufacturers/sponsors</strong></td>
<td><strong>General</strong></td>
</tr>
<tr>
<td>• Abbott Laboratories (adalimumab)</td>
<td>• Age Concern Cymru</td>
</tr>
<tr>
<td>• Bristol-Myers Squibb (abatacept)</td>
<td>• Board of Community Health Councils in Wales</td>
</tr>
<tr>
<td>• Roche Products (rituximab)</td>
<td>• British National Formulary</td>
</tr>
<tr>
<td>• Schering-Plough (infliximab)</td>
<td>• Department of Health, Social Services and Public Safety for Northern Ireland</td>
</tr>
<tr>
<td>• Wyeth Pharmaceuticals (etanercept)</td>
<td>• Medicines and Healthcare products Regulatory Agency (MHRA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Patient/carer groups</strong></th>
<th><strong>Possible comparator manufacturer(s)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Action on Pain</td>
<td>• Actavis (azathioprine, sulfasalazine, penicillamine)</td>
</tr>
<tr>
<td>• Afiya Trust</td>
<td>• Alliance Pharmaceuticals (penicillamine)</td>
</tr>
<tr>
<td>• Age Concern England</td>
<td>• Almus Pharmaceuticals (sulfasalazine)</td>
</tr>
<tr>
<td>• Arthritic Association</td>
<td>• Arrow Generics (azathioprine)</td>
</tr>
<tr>
<td>• Arthritis &amp; Musculoskeletal Alliance (ARMA)</td>
<td>• Astellas (auranofin)</td>
</tr>
<tr>
<td>• Arthritis Care</td>
<td>• AstraZeneca UK (chloroquine)</td>
</tr>
<tr>
<td>• BackCare</td>
<td>• Focus Pharmaceuticals (azathioprine)</td>
</tr>
<tr>
<td>• Black Health Agency</td>
<td>• Generics (UK) (azathioprine, sulfasalazine, penicillamine)</td>
</tr>
<tr>
<td>• Brain and Spine Foundation</td>
<td>• GlaxoSmithKline (azathioprine)</td>
</tr>
<tr>
<td>• British Ethnic Health Awareness Foundation (BEHAF)</td>
<td>• IVAX Pharmaceuticals (azathioprine, sulfasalazine)</td>
</tr>
<tr>
<td>• Chinese National Healthy Living Centre</td>
<td></td>
</tr>
<tr>
<td>• Confederation of Indian Organisations</td>
<td></td>
</tr>
<tr>
<td>• Counsel and Care</td>
<td></td>
</tr>
<tr>
<td>• Equalities National Council</td>
<td></td>
</tr>
<tr>
<td>• Help the Aged</td>
<td></td>
</tr>
<tr>
<td>• Leonard Cheshire Disability</td>
<td></td>
</tr>
<tr>
<td>• Muslim Council of Great Britain</td>
<td></td>
</tr>
<tr>
<td>• Muslim Health Network</td>
<td></td>
</tr>
<tr>
<td>• National Rheumatoid Arthritis Society</td>
<td></td>
</tr>
<tr>
<td>• Pain Concern</td>
<td></td>
</tr>
<tr>
<td>• Pain Relief Foundation</td>
<td></td>
</tr>
</tbody>
</table>

National Institute for Health and Clinical Excellence – Provisional matrix for the appraisal of Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

Issue date: February 2009
### Consultees
- Royal Association for Disability & Rehabilitation (RADAR)
- South Asian Health Foundation
- Specialised Healthcare Alliance

### Professional groups
- British Association for Services to the Elderly
- British Geriatrics Society
- British Health Professionals in Rheumatology
- British Institute of Musculoskeletal Medicine
- British Orthopaedic Association
- British Pain Society
- British Society for Rheumatology
- British Society of Rehabilitation Medicine
- Physiotherapy Pain Association
- Primary Care Rheumatology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine – Intellectual Disabilities Forum
- United Kingdom Clinical Pharmacy Association

### Others
- Department of Health
- Derby City PCT
- Ealing PCT
- Welsh Assembly Government

### Commentators (no right to submit or appeal)
- Mayne Pharma (methotrexate)
- Medac UK (methotrexate)
- Novartis (cyclosporin)
- Pfizer (methotrexate, sulfasalazine)
- Roche Products (tocilizumab)
- Sandoz (azathioprine)
- Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate)
- Schering Plough (golimumab)
- Teva UK (azathioprine, sulfasalazine, penicillamine)
- UCB Pharma (certolizumab pegol)
- Waymade Healthcare (sulfasalazine)
- Wockhardt UK (methotrexate)

### Relevant research groups
- Arthritis Research Campaign
- Chronic Pain Policy Coalition
- MRC Clinical Trials Unit
- National Institute for Health Research
- Policy Research Institute on Ageing and Ethnicity
- Research Institute for the Care of Older People
- Society for Back Pain Research
- United Kingdom Clinical Research Network

### Assessment Group
- TBC
- National Institute for Health Research Health Technology Assessment Programme

### Associated Guideline Groups
- National Collaborating Centre for Chronic Conditions
- Scottish Intercollegiate Guidelines Network (SIGN)

### Associated Public Health Groups
- None
NICE is committed to promoting equality and eliminating unlawful discrimination.
Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS
Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technologies based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

1 Non manufacturer consultees are invited to submit statements relevant to the group they are representing.